Description
Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a agent-linker conjugate for ADC.–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-programmed cell death-Formula-C51H77N7O9S-Citation–References-[1]Antibody-drug conjugates Patent: WO 2013068874 A1-CASNumber-1401963-15-2-MolecularWeight-964.26-Compound Purity-98.50-SMILES-O=C1N(CCCCCC(N(C)[C@H](C(N[C@@H](C(C)C)C(N(C)[C@]([C@@H](C)CC)([H])[C@@H](CC(N2[C@H]([C@H](OC)[C@H](C(N[C@@H](CC3=CC=CC=C3)C4=NC=CS4)=O)C)CCC2)=O)OC)=O)=O)C(C)C)=O)C(C=C1)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 100 mg/mL-Target-Drug-Linker Conjugates for ADC;Microtubule/Tubulin-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related
